Glaucoma: An Open-Window to Neurodegeneration and Neuroprotection

Carlo Nucci is Professor of Ophthalmology in the Ophthalmology Unit, Department of Experimental Medicine at the University of Rome Tor Vergata, Italy. Giacinto Bagetta is Professsor of Pharmacology and works in the Department of Pharmacy, Health Science and Nutritionat University of Calabria, Arcavata di Rende, Italy.

• EPIDEMIOLOGY AND CLINICAL ASSESSMENT OF THE DISEASE1. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effectsC. Cedrone, R. Mancino, A. Cerulli, M. Cesareo and C. Nucci (Italy)2. Predictive models to estimate the risk of glaucoma development and progressionF.A. Medeiros and R.N. Weinreb (USA)3. Intraocular pressure and central corneal thicknessG. Manni, F. Oddone, V. Parisi, A. Tosto and M. Centofanti (Italy)4. Angle-closure: risk factors, diagnosis and treatment N. Amerasinghe and T. Aung (Singapore)5. Early diagnosis in glaucomaD.F. Garway-Heath (UK, Italy)6. Monitoring glaucoma progressionP. Brusini (Italy)ANATOMICAL AND FUNCTIONAL MONITORING7. Standard automated perimetry and algorithms for monitoring glaucoma progressionsG.L. Scuderi, M. Cesareo, A. Perdicchi and S.M. Recupero (Italy)8. Short-wavelength automated perimetry and frequency-doubling technology perimetry in glaucomaP. Fogagnolo, L. Rossetti, S. Ranno, A. Ferreras and N. Orzalesi (Italy, Spain)9. Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucomaF. Ferreri, P. Aragona and G. Ferreri (Italy)10. The role of OCT in glaucoma management (Italy)11. Functional laser Doppler flowmetry of the optic nerve: physiological aspects and clinical applicationsC.E. Riva and B. Falsini (Italy)12. Advances in neuroimaging of the visual pathways and their use in glaucomaF.G. Garaci, V. Cozzolino, C. Nucci, F. Gaudiello, A. Ludovici, T. Lupattelli, R. Floris and G. Simonetti (Italy)CURRENT THERAPY13. Primary open angle glaucoma: an overview on medical therapyM. Vetrugno, F. Cantatore, G. Ruggeri, P. Ferreri, A. Montepara, A. Quinto and C. Sborgia (Italy)14. The treatment of normal tension glaucomaP.V. Desai and J. Caprioli (USA)15. The management of exfoliative glaucomaR. Rich (USA)16. Laser therapies for glaucoma: new frontiersG.L. Scuderi and N. Pasquale (Italy)17. Modulation of wound healing during and after glaucoma surgeryS. Georgoulas, A. Dahlmann-Noor, S. Brocchini and P.-T. Khaw (UK)18. Surgical alternative to trabeculectomyR.G. Carassa (Italy)19. Modern aqueous shunt implantation ¡§C future challengesK. Barton and D.K. Heuer (London, UK and Milwaukee, USA)EXPERIMENTAL APPROACHES TO MODEL DISEASE20. Model systems for experimental studies: retinal ganglion cells in cultureE. Goodyear, and L.A. Levin (Canada)21. Rat models for glaucoma researchJ.C. Morrison, E. Johnson and W.O. Cepurna (USA)22. Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotectionR. Howell, R.T. Libby and S.W.M. John (USA)23. Clinical trials in neuroprotectionS.M. Whitcup (USA)NEUROPROTECTION: NEW VISTAS IN PATHOPHYSIOLOGY24. Pathogenesis of ganglion cells in glaucoma and neuroprotection: Focus on ganglion cell axonal mitochondria N.N. Osborne (UK)25. Astrocytes in glaucomatous optic neuropathyM.R. Hernandez, H. Miao and T. Lukas (USA)26. Glaucoma as a neuropathy amenable to neuroprotection and immune manipulationM. Schwartz and A. London (Israel)27. Oxidative stress and glaucoma. Injury in the anterior segment of the eyeS.C. Sacca and A. Izzotti (Italy)28. TNF-alpha signalling in glaucomatous neurodegenerationG. Tezel (USA)29. Involvement of the Bcl2 gene family in the signalling and control of retinal ganglion cell death R.W. Nickells, S.J. Semaan and C.L. Schlamp (USA)30. Assessment of neuroprotection in the retina with DARCL.Guo and M.F. Cordeiro (UK)31. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotectionC. Nucci, M. Bari, A. Spano, M.T. Corasaniti,, G. Bagetta, M. Maccarrone and L.A. Morrone (Italy)32. Glaucoma of the brain: a disease model for the study of transsynaptic neural degenerationY. Yücel and N. Gupta (USA)33. Changes of central visual receptive fields in experimental glaucomaS.C. Sharma (USA)NEUROPROTECTION: EVIDENCE FOR FUTURE STRATEGIES34. Targeting excitotoxic/free radical signalling pathways for therapeutic intervention in glaucomaM. Seki and S.A. Lipton (USA)35. Stem cells for neuroprotection in glaucomaN.D. Bull, T.V. Johnson and K.R. Martin (UK)36. The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cellsN.G.F. Cooper, A. Laabich, W. Fan and X. Wang (USA)37. Evidence of the neuroprotective role of Citicoline in glaucoma patientsV. Parisi, G. Coppola, M. Centofanti, F. Oddone, A.-M. Angrisani, L. Ziccardi, B. Ricci, L. Quaranta and G. Manni (Italy)38. Neuroprotection: VEGF, IL-6 and cluster in the dark side of the moonS. Pucci, P. Mazzarelli, F. Missiroli, F. Regine and F. Ricci (Italy)39. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protectionR. Russo, F. Cavaliere, L. Rombol¡§¡è, M. Gliozzi, A. Cerulli, C. Nucci, E. Fazzi, G. Bagetta, M.T. Corasaniti and L.A. Morrone (Italy)40. 17 beta-estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in ratR. Russo, F. Cavaliere F., C. Watanabe, C. Nucci, G. Bagetta, M. T. Corasaniti, S. Sakurada and L. A. Morrone (Italy, Japan)